Evidence map›Paper›PMID 41942778›Full record

ArticleAnnals of surgical oncology2026

Patterns, Timing, and Survival of Recurrence After Surgery for Esophageal and Junctional Adenocarcinoma in the European Multicentre ENSURE Study.

Lucas Goense, Jessie A Elliott, Sheraz R Markar, Fredrik Klevebro, Asif Johar, Styliani Mantziari, Pernilla Lagergren, Giovanni Zaninotto, Richard van Hillegersberg, Mark I van Berge Henegouwen and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lucas GoenseDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. L.Goense@umcutrecht.nl.
Jessie A ElliottDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Sheraz R MarkarNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Fredrik KlevebroDepartment of Clinical Science Intervention and Technology (CLINTEC), Department of Upper Abdominal Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Asif Johar
Styliani MantziariLausanne University Hospital CHUV, Lausanne, Switzerland.
Pernilla LagergrenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Giovanni ZaninottoDepartment of Surgery and Cancer, Imperial College London, St. Mary's Hospital, London, UK.
Richard van HillegersbergDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Mark I van Berge HenegouwenDepartment of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Magnus NilssonDepartment of Clinical Science Intervention and Technology (CLINTEC), Department of Upper Abdominal Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
George B HannaDepartment of Surgery and Cancer, Imperial College London, St. Mary's Hospital, London, UK.
John V ReynoldsTrinity St. James's Cancer Institute, Trinity College Dublin, St. James's Hospital, Dublin, Ireland.
ENSURE Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFollowing surgery for esophageal cancer, approximately half of patients develop disease recurrence. Analyzing recurrence site, timing, and their impact on postrecurrence survival can guide refinements in postoperative surveillance and therapy. This study aimed to describe the pattern and timing of esophageal cancer recurrence and assess survival patterns by recurrence location.

methodsThis study included patients from the ENSURE study who underwent resection for esophageal and junctional adenocarcinoma between 2009 and 2015 across 20 centers in Europe and Canada. Only patients with disease recurrence were included in the final analysis. Sites of first recurrence were stratified into different groups and survival outcomes postrecurrence detection were estimated using Kaplan-Meier curves.

resultsOf 3,299 patients who underwent surgery for esophageal adenocarcinoma, 1,310 patients developed recurrence and had sufficient follow-up data available. First recurrence was detected at multiple distant sites (n = 469; 37.3%) or at a single distant site (n = 463; 33.7%), whereas isolated local recurrence occurred in 189 (14.4%) patients. Recurrence in the liver-only presented significant earlier (median 9.0 months), whereas recurrence in lung-only (15.2 months) and local-only recurrence (17.8 months) were observed later. Patients with multiple-sites and liver-only recurrence had significant worse median postrecurrence survival (7.4 and 8.3 months, respectively) compared with lung- or local-only recurrence (10.4 and 15.9 months, respectively).

conclusionsThis study highlights that time to recurrence varies by location and significantly impacts postrecurrence survival outcomes. Multiple sites and liver-only recurrence had the poorest prognosis.

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagectomyEsophagogastric JunctionLiver NeoplasmsNeoplasm Recurrence, LocalAgedEuropeFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisSurvival RateTime FactorsEsophageal adenocarcinomaLocoregional recurrenceMetastatic sitesPost-recurrence survivalRecurrence-free intervalRecurrence patterns

Identifiers

PMID41942778
PMCPMC13242413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.